In the past, the standard treatment for Chronic Lymphocytic Leukemia included a combination of chemotherapy and immunotherapy agents such as chlorambucil, fludarabine or bendamustine in combination with rituximab or obinutuzumab. Over the last few years, a better understanding of the biology of Chronic Lymphocytic Leukemia has led to major breakthroughs with a number of more targeted therapies being developed to treat Chronic Lymphocytic Leukemia. As such, a chemo-free approach to Chronic Lymphocytic Leukemia is now a reality. These drugs are directed at specific proteins that help Chronic Lymphocytic Leukemia cells grow. Examples of targeted drugs for Chronic Lymphocytic Leukemia include ibrutinib, acalabrutinib, venetoclax, idelalisib and duvelisib.